NobleCon 18. Kenneth Londoner, Chairman and CEO, presented at the conference. The presentation highlighted the PURE EP market opportunity, growth in procedure usage, and commercialization strategy. A presentation replay can be found Here.Expanding usage. PURE EP has now been used in over 2200 procedures at 17 sites, showing sequential quarterly growth every quarter. This is a strong indication of demand and need for the technology, despite some pandemic headwinds. AFib is the fastest growing sector in cardiology, with one in four over the age of 60 having AFib, so need should only increase.A new phase in commercialization. With a new team in place and, given PURE EP's compelling clinical and economic data, Gray Fleming, CCO, and John Sieckhaus, COO, are moving to a new national strategy, going from a more regional focus. The recently announced leasing option could shorten the sales cycle by attacking operating budget spending compared to capital budgets, with an expected 60-70% of PURE EP units being leased. In addition, having contracted with Plexus as manufacturer, the Company feels they are better positioned with supply to go national.Access Strategy Partners going after IDNs and GPOs. Collaborating with BioSig Technologies, Access Strategy Partners has expertise in engaging with large delivery networks and group purchasing organizations and optimizing value propositions. Getting on contract with these organizations will clear the way for hospitals to access PURE EP.Maintaining Outperform. Commercialization efforts underway are expected to advance PURE EP as a desirable, if not "must-have" component of electrophysiology labs in the U.S. and abroad. We are keeping our one-year price target at $4.00. Our target is based on expected $0.55 2027 EPS, discounted 20% and applying a 20x multiple. Read More >>